Clee Medical, a Swiss
neurotechnology startup developing ultra-high-resolution real-time imaging for
brain surgery, has closed its seed financing round. The round was led by
High-Tech Gründerfonds (HTGF), with participation from Zürcher Kantonalbank
(ZKB), Kickfund, FONGIT, and Venture Kick, alongside continued support from
existing partner Wyss Geneva.
Many neurosurgical
procedures require navigating delicate brain structures with millimetre-level
precision, yet anatomical shifts and limited intraoperative visibility can make
targeting during surgery challenging. Clee Medical is developing minimally invasive
neurotechnology solutions to address this gap.
Founded in October 2024 by
Matt Lapinski and Abed Hammoud, the company’s flagship Neuro Access platform
combines ultra-high-resolution real-time intraoperative Optical Coherence
Tomography imaging with advanced navigation capabilities to support precision
neurosurgery. The technology is designed to provide real-time imaging inside
the brain, helping surgeons navigate complex anatomy with greater confidence
and enabling safer access to deep brain targets for more targeted
neurotherapies.
Built on years of
translational research, the platform is being developed to support applications
including functional neurosurgery and neuro-oncology.
With the new financing,
Clee Medical plans to expand its development and clinical programs, advance toward
its first-in-human clinical study, and accelerate the clinical validation of
Neuro Access.
The company’s long-term vision is to enable
neurosurgeons to operate with enhanced real-time insight, improving safety,
efficiency, and patient outcomes in complex brain procedures.